miR-23a与RUNX1在恶性淋巴瘤中的表达及其临床意义

Expression and Clinical Significance of miR-23a and RUNX1 in Malignant Lymphomas

目的:探讨miR-23a与runt相关转录因子(runt-related transcription factor 1,RUNX1)在恶性淋巴瘤中的表达及临床意义。方法:运用荧光素酶报告基因活性分析检测miR-23a与RUNX1基因3′UTR区结合情况。收集150例恶性淋巴瘤及30例反应性增生淋巴组织手术标本,分别运用原位杂交、免疫组织化学方法检测两组中miR-23a、RUNX1的表达。结果:RUNX1是miR-23a直接调控的靶基因。miR-23a在150例恶性淋巴瘤组织中阳性表达率为66.7%,显著高于反应性增生淋巴组织(30.0%,P<0.01),且与肿瘤恶性程度和临床分期密切相关(P<0.01);RUNX1蛋白在150例恶性淋巴瘤组织中阳性表达率为24.7%,显著低于反应性增生淋巴组织(53.3%,P<0.01),且与肿瘤组织学类型、恶性程度和临床分期密切相关(P<0.05);相关性分析表明,miR-23a与RUNX1的表达呈负相关(P<0.01)。结论:RUNX1是miR-23a直接调控的靶基因,miR-23a的高表达和RUNX1蛋白低表达可能是恶性淋巴瘤发生发展的重要生物学标志。

Objective： To investigate the expression and clinical significance of miR-23a and RUNX1 in malignant lymphomas. Methods： Luciferase reporter gene activity was used to evaluate miR-23 a targeting of RUNX 1. A total of 150 cases with malignant lym- phomas and 30 cases with lymphatic tissues with reactive hyperplasia were collected. Hybridization in situ and immunohistochemistry were used to determine the miR-23a and RUNX1 expression in the two groups, respectively. Results： MiR-23a was bound to the RUNX1 3＇UTR. The positive expression rate of miR-23a was 66.7 % in the malignant lymphomas, significantly higher than that in the lymphatic tissues with reactive hyperplasia （ 30.0 %; P 〈 0.01 ）. This high expression was significantly correlated with the degree of malignancy and clinical stage （ P 〈 0.01 ）. The positive expression rate of RUNX1 was 24.7 % in malignant lymphomas, significantly lower than that in the lymphatic tissues with reactive hyperplasia （ 53.3 %; P 〈 0.01 ）. This low expression was significantly correlated with histological type, degree of malignancy, and clinical stage （ P 〈 0.05 ）. The expression of rniR-23a was negatively correlated with that of RUNX1 （ P 〈 0.01 ）. Conclusion： RUNX1 is the target gene of miR-23a. The high expression of miR-23a and lower expression of RUNX1 protein may be important biological markers for the onset and progression of malignant lymphoma.